fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New guidelines for managing blood cancers in pregnancy

Written by | 5 Jan 2025

A new set of guidelines has been developed to assist with the diagnosis and expert management of serious blood cancers in pregnancy. About 12.5 pregnancies per 100,000 are… read more.

Roche presents long term outcomes and innovative therapies in hematology at ASH 2024

Written by | 2 Dec 2024

Roche announced  that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December… read more.

NICE (UK) positive for Fabhalta (iptacopan) to treat paroxysmal nocturnal haemoglobinuria – Novartis

Written by | 20 Sep 2024

Iptacopan is recommended, within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic anaemia. Iptacopan is only recommended if the company… read more.

Sylvester research shows new treatment may enable more patients with high-risk blood cancers to receive stem cell transplants

Written by | 3 Jun 2024

A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to… read more.

Nation’s newest, most comprehensive blood cancer healing center to transform care landscape

Written by | 17 Feb 2024

The Blood Cancer Healing Center, located at 3229 Burnet Avenue in Uptown Cincinnati, is poised to redefine care standards by offering comprehensive patient support and innovative treatments under… read more.

ZORA real-world evidence demonstrates that Lokelma substantially increases cardiorenal patients’ chances of maintaining lifesaving RAASi therapy in hyperkalaemia patients – AstraZeneca

Written by | 10 Nov 2023

Results from the real-world ZORA observational multi-country study presented at the American Society of Nephrology (ASN) 2023 shows that treating hyperkalaemia (HK) with the potassium binder Lokelma (sodium… read more.

New insights to enhance treatment and diagnosis of blood cancer

Written by | 17 Sep 2023

A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has revealed crucial insights into the role of the… read more.

BioMarin announces first person treated commercially with Roctavian for severe hemophilia A in Europe

Written by | 2 Sep 2023

BioMarin Pharmaceutical Inc. announced that an individual in Germany with severe hemophilia A was treated with Roctavian (valoctocogene roxaparvovec-rvox), marking the first time that the gene therapy has… read more.

New research shows promise for drug to lessen side effects of blood thinning drugs for stroke patients with bleeding in the brain

Written by | 8 Jul 2023

The results of a clinical trial have shown that a drug commonly used for patients with bleeding disorders has the potential to be used to lessen the side… read more.

CHMP extends the indication of Refixia to prophylaxis of bleeding in patients 12 years and above with haemophilia B – Novo Nordisk

Written by | 30 Jun 2023

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Refixia…. read more.

New data informs treatment of blood cancer during pregnancy

Written by | 6 Jun 2023

Today, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival rate of 24% and an overall survival rate of 83%…. read more.

Monthly injections of fitusiran reduces bleeds in patients with haemophilia A and B

Written by | 2 Apr 2023

Monthly prophylactic injections of fitusiran are effective in reducing bleeds in patients with haemophillia A or B, according to randomised controlled trials publishing simultaneously in The Lancet and The Lancet Haematology journals…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.